藤原 篤之
   Department     ,
   Position  
Article types 原著
Language English
Peer review Peer reviewed
Title One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.
Journal Formal name:Japanese journal of ophthalmology
Abbreviation:Jpn J Ophthalmol
ISSN code:16132246/00215155
Domestic / ForeginForegin
Volume, Issue, Page 61(2),150-158頁
Author and coauthor Hosokawa Mio, Morizane Yuki, Hirano Masayuki, Kimura Shuhei, Kumase Fumiaki, Shiode Yusuke, Doi Shinichiro, Toshima Shinji, Hosogi Mika, Fujiwara Atsushi, Mitsuhashi Toshiharu, Shiraga Fumio
Publication date 2017/03
Summary PURPOSE:To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV).METHODS:Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed.RESULTS:The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval.CONCLUSIONS:IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.
DOI 10.1007/s10384-016-0492-7
PMID 27928695